<DOC>
	<DOCNO>NCT00606580</DOCNO>
	<brief_summary>This study test ability topical cream WR 279,396 treat skin lesion cause parasite call leishmania . WR 279,396 antibiotic preparation contains paromomycin + gentamicin . This cream compare effect topical cream contain paromomycin alone placebo cream contain antibiotic . Therefore , study three group patient , assign one treatment randomly . The study carry without patient physician know cream use patient . The goal determine WR 279,396 cream paromomycin cream well placebo , WR 279,396 good paromomycin alone .</brief_summary>
	<brief_title>Phase 3 Study Evaluate WR 279,396 vs. Paromomycin Alone Treat Cutaneous Leishmaniasis ( Tunisia )</brief_title>
	<detailed_description>This efficacy study test ability WR 279,396 topical cream treat uncomplicated cutaneous leishmaniasis cause primarily Leishmania major adult child Tunisia disease endemic . A total 375 volunteer randomize three arm describe determine product efficacy . Safety data three arm also collect .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<mesh_term>Paromomycin</mesh_term>
	<criteria>The subject age 5 year old , less 65 year . The subject able understand information provide him/her give write informed consent . Consent obtain parent/guardian subject &lt; 18 year old . Children 12 &lt; 18 year old ask sign write assent form . Witnessed verbal assent obtain subject 5 11 year old . The subject male female generally healthy . The subject cutaneous lesion diagnose leishmaniasis index lesion : ( 1 ) identification promastigotes culture aspirate lesion , ( 2 ) microscopic identification Leishmania amastigotes DifQuik Giemsa stain smear obtain lesion scrap . The subject five few cutaneous lesion . The subject one lesion , would designate index lesion , ≥ 1 &lt; 5 cm great diameter primarily ulcerative , ie , purely verrucous nodular . The subject willing forego form treatment CL , include investigational treatment study . In opinion principal investigator , subject subject 's parent/guardian capable understand comply protocol Exclusion Criteria The subject receive previous treatment leishmaniasis ( include WR 279,396 ) within last 6months , exception mercurochrome . The subject difficulty comply instruction maintain dressing , eg , due life style activity age . The subject single lesion whose characteristic include follow : verrucous nodular lesion , ≥ 5 cm great diameter , &lt; 1 cm locate ear , location opinion principal investigator would difficult maintain application study drug topically . The subject lesion due Leishmania involve mucosa . The subject sign symptom disseminate disease , ie , clinically significant lymphadenitis nodule painful &gt; 1 cm lymphatic drainage ulcer . The subject female positive urine pregnancy test , breast feeding lactating . The subject active malignancy history solid , metastatic hematologic malignancy , exception basal squamous cell carcinoma skin remove . The subject significant organ abnormality chronic disease , opinion investigator , would warrant exclusion subject study would prevent subject complete study . The subject receiving follow medication : medication contain pentavalent antimony , include stibogluconate sodium ( Pentostam® ) meglumine antimoniate ( Glucantime® ) ; amphotericin B , include liposomal amphotericin B amphotericin B deoxycholate ; medication contain paromomycin ( administer IV topically ) ; methylbenzethonium chloride , fluconazole , ketoconazole , itraconazole ; pentamidine ; allopurinol . The subject subject 's parent/guardian unable understand verbal and/or write Arabic , English , French ( language certify translation inform consent available ) . The subject present immunocompromising condition , include recidivant leishmaniasis ( past 2 year ) , diabetes . The subject history know suspected idiosyncratic reaction hypersensitivity aminoglycosides .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>cutaneous leishmaniasis , topical treatment , Tunisia</keyword>
</DOC>